Biotech Runners: Osiris Therapeutics (NASDAQ:OSIR) and Gilead Sciences (NASDAQ:GILD)

Stamford, CT -- (SBWIRE) -- 03/11/2013 -- Jet Life Penny Stocks provides investors with the hot penny stock alerts on a regular basis. We will send you alerts through our Penny Stock Newsletters and offer you the tools to help you along the way with the goal of keeping you loyal to our service.

Gilead Sciences Inc's (NASDAQ:GILD) angina medicine Ranexa lowered chances of chest pain in patients with diabetes, and the effect seemed to be more distinct in those with poor blood sugar control, as per reported by data from a clinical experiment.

Ranexa, recognized chemically as ranolazine, is formerly approved to cure angina - a kind of chest pain linked with heart disease. This was the initially experimented to test it especially in diabetics, who tend to have more problems and can be more hard to cure that other heart patients.

In the eight-week, 927-patient research, called as Terisa, those taking Ranexa announced an average of 3.8 weekly episodes of chest pain in contrasted with 4.3 for the placebo group. The data was given on Sunday at the American College of Cardiology (ACC) scientific gathering in San Francisco.

How shares of Gilead Sciences responded on Monday session? Find in this report

Stock of Gilead Sciences (NASDAQ:GILD) was trading below the trend line with negative change of -0.04% on Monday trading session.

How Osiris shares gained ground on Monday? Find out in this report

Osiris Therapeutics (NASDAQ:OSIR), Stem cell firm Osiris rallied 35% last week following announcing a lower than predicted loss for its fourth quarter.

The company declined to a loss of $2.6 million (8 cents per share) following announcing a $5.05 million (15-cent) profit in the year-earlier phase, but that topped experts predictions of a $5 million loss.

The firm’s $3.1 million in revenues also topped expert prediction for $2.9 million. Osiris presently has a Phase 3 product, Prochymal that is being checked for many uses, counting as a treatment for Crohn’s disease and heart tissue repair.

About Jetlifepennystock.com
Jet Life Penny Stocks is always searching the market every day for massive penny stock runs before they happen so you don't have to. Jet Life Penny Stocks also offers free Highly-Professional Grade stock charts and video charts from one of the most experienced and well-respected chartists in the penny stock industry.

Disclaimer
Jet Life Penny Stocks is not a registered securities advisor. Investors should always conduct their own additional due diligence with any potential investment or highlighted company. The company provides information on highlighted stocks via press releases, newsletters and company website, but this should not be construed as a recommendation to buy or sell. Please visit the company website for a more complete list of risks and disclosures.